Interventional & Preventive Cardiology · Physician-Investor Briefing

Anticoagulants and Antiplatelets in 2026: A Complete Field Guide by Indication

Every major antithrombotic class in current use, mapped to the indications that drive real prescribing decisions, plus the reversal-agent shakeup and pipeline drugs worth watching.

Clinical Review·Updated July 2026·~14 min read

Cardiologists juggle two distinct antithrombotic toolkits every day: anticoagulants, which interrupt the coagulation cascade, and antiplatelets, which block platelet activation and aggregation.

The two classes are not interchangeable, and the indication almost always dictates the choice: atrial fibrillation and venous thromboembolism are anticoagulant territory, while acute coronary syndrome and percutaneous coronary intervention are built around antiplatelet therapy, often layered on top of an anticoagulant.

This briefing organizes both drug classes by mechanism and then by the clinical indication that should drive selection, and it folds in the reversal-agent shakeup from late 2025 and the factor XIa pipeline that could reshape the field again before this decade is out.

In This Article

1. Anticoagulants: Vitamin K Antagonism Through DOACs
2. Antiplatelets: Aspirin Through GPIIb/IIIa Inhibitors
3. The Reversal-Agent Landscape Just Changed
4. Quick Reference by Indication
5. What's Next: Factor XIa Inhibitors

Anticoagulants: Vitamin K Antagonism Through DOACs

Warfarin (brand names Coumadin and Jantoven) remains the only oral anticoagulant with decades of outcome data in mechanical heart valves and moderate-to-severe mitral stenosis, populations excluded from every DOAC trial.

It works by inhibiting hepatic synthesis of vitamin K–dependent clotting factors II, VII, IX, and X, which is also why it requires routine INR monitoring and carries a target range of 2.0–3.0 for most indications, or 2.5–3.5 for mechanical mitral valves.

Generic warfarin is inexpensive, typically under $10 per month at most retail pharmacies according to GoodRx pricing data, which keeps it relevant in resource-limited settings and for patients who cannot afford brand-name DOACs.

Four direct oral anticoagulants now anchor most anticoagulation decisions in nonvalvular atrial fibrillation, venous thromboembolism, and post-orthopedic prophylaxis.

Apixaban (Eliquis) remains the most widely prescribed DOAC in the United States and is now Medicare's highest-spend Part D drug, at an estimated $16.5 billion in annual program cost.

Rivaroxaban (Xarelto) offers once-daily dosing and the broadest label of the group, spanning atrial fibrillation, venous thromboembolism, and secondary prevention in stable coronary and peripheral artery disease at a reduced "vascular dose," often paired with aspirin under a dual-pathway inhibition strategy.

Dabigatran (Pradaxa) is the only DOAC dosed as a direct thrombin inhibitor rather than a factor Xa blocker, and it is the only one with a long-standing FDA-approved specific reversal agent.

Edoxaban (Savaysa in the U.S., marketed as Lixiana outside the U.S.) rounds out the class with once-daily dosing, though a label caveat limits its use in patients with very high creatinine clearance for atrial fibrillation indications.

Anticoagulant Comparison and Pricing Snapshot

Agent	Brand	Mechanism	Key Indications	GoodRx Cash Price*	Company / Ticker
Apixaban	Eliquis	Factor Xa inhibitor	AF stroke prevention, VTE tx/prevention	~$348–630/mo	NYSE: BMY NYSE: PFE
Rivaroxaban	Xarelto	Factor Xa inhibitor	AF, VTE, CAD/PAD secondary prevention	~$37 coupon low / ~$470 retail	NYSE: JNJ OTC: BAYRY
Dabigatran	Pradaxa	Direct thrombin inhibitor	AF stroke prevention, VTE tx/prevention	~$36–46/mo generic	Boehringer Ingelheim (private)
Edoxaban	Savaysa	Factor Xa inhibitor	AF (CrCl-limited), VTE tx	~$423–515/mo	OTC: DSNKY
Warfarin	Coumadin / Jantoven	Vitamin K antagonist	Mechanical valves, mitral stenosis, AF, VTE	~$4–10/mo generic	Multiple generic manufacturers

*Cash prices vary by pharmacy and are time-sensitive; figures reflect GoodRx-listed ranges as of mid-2026 and exclude insurance-negotiated or Medicare IRA prices.

Each anticoagulant class interrupts the cascade at a different point; factor XIa inhibitors target upstream amplification rather than the common pathway, which is the theoretical basis for their lower bleeding signal.

Antiplatelets: Aspirin Through GPIIb/IIIa Inhibitors

Aspirin remains the foundation of antiplatelet therapy across nearly every cardiovascular indication, irreversibly inhibiting COX-1 to block thromboxane A2–driven platelet aggregation at a cost of just a few dollars a month according to GoodRx.

The P2Y12 inhibitor class sits on top of aspirin in most acute coronary syndrome and post-PCI regimens, and the three oral agents differ meaningfully in onset, potency, and bleeding risk.

Clopidogrel (Plavix) is the least potent but cheapest and most extensively studied option, now available as a low-cost generic for as little as $4.50 per month with a coupon, though reduced-function CYP2C19 metabolizers get less benefit from it.

Ticagrelor (Brilinta) is a reversible-binding agent with faster onset and stronger platelet inhibition than clopidogrel, and it carries a Class I recommendation across most acute coronary syndrome guidelines regardless of genotype.

Prasugrel (Effient) offers the most potent platelet inhibition of the oral agents but is restricted to patients undergoing PCI and is generally avoided in those 75 years or older, under 60 kg, or with prior stroke or TIA given its bleeding profile.

Cangrelor (Kengreal) is the only intravenous P2Y12 inhibitor, valued in the cath lab for its rapid onset and equally rapid offset within about an hour of stopping the infusion, useful when oral absorption is unreliable or a bridge to surgery is needed.

The GPIIb/IIIa inhibitors — abciximab (ReoPro), eptifibatide (Integrilin), and tirofiban (Aggrastat) — block the final common pathway of platelet aggregation and are reserved almost exclusively for high-thrombus-burden PCI or bailout situations given their bleeding and thrombocytopenia risk.

Vorapaxar (Zontivity) is a PAR-1 antagonist added on top of aspirin and/or a P2Y12 inhibitor for secondary prevention after myocardial infarction or in symptomatic PAD, but it is contraindicated in anyone with a history of stroke, TIA, or intracranial hemorrhage.

Antiplatelet Comparison and Pricing Snapshot

Agent	Brand	Class	Route	Typical Cash Price*	Company / Ticker
Aspirin	Various	COX-1 inhibitor	Oral	~$4–7/mo	Multiple OTC manufacturers
Clopidogrel	Plavix	P2Y12 inhibitor (irreversible)	Oral	~$4.50–25/mo generic	Multiple generic manufacturers
Ticagrelor	Brilinta	P2Y12 inhibitor (reversible)	Oral	~$25–35/mo coupon	NASDAQ: AZN
Prasugrel	Effient	P2Y12 inhibitor (irreversible)	Oral	~$9–29/mo generic	OTC: DSNKY / Eli Lilly
Cangrelor	Kengreal	P2Y12 inhibitor (IV)	Intravenous	Inpatient/hospital billed	Chiesi Farmaceutici (private)
Eptifibatide	Integrilin (generic only)	GPIIb/IIIa inhibitor	Intravenous	~$31–92/vial	Multiple generic manufacturers
Tirofiban	Aggrastat	GPIIb/IIIa inhibitor	Intravenous	Inpatient/hospital billed	OTC: MCUJF
Abciximab	ReoPro	GPIIb/IIIa inhibitor	Intravenous	Inpatient/hospital billed; limited current use	Legacy branded product
Vorapaxar	Zontivity	PAR-1 antagonist	Oral	Variable, brand-only	NYSE: MRK

*IV agents are hospital-administered and typically billed as part of the procedure rather than filled at retail pharmacies; prices shown are wholesale/vial references and are time-sensitive.

Aspirin and vorapaxar act on distinct upstream activation pathways, while P2Y12 and GPIIb/IIIa inhibitors converge on the platelet surface receptors that drive final aggregation.

The Reversal-Agent Landscape Just Changed

Anyone managing DOAC-associated bleeding needs to know that andexanet alfa (Andexxa) is no longer available in the United States.

The FDA safety communication issued in December 2025 reported that the confirmatory ANNEXA-I trial found thrombotic events in 14.6% of andexanet-treated patients versus 6.9% with usual care, alongside a near-tripling of thrombosis-related death.

AstraZeneca voluntarily withdrew the biologics license and ended U.S. commercial sales on December 22, 2025, which means 4-factor prothrombin complex concentrate (Kcentra) is now the de facto standard of care for reversing apixaban- or rivaroxaban-associated life-threatening bleeding.

Idarucizumab (Praxbind) is unaffected by this withdrawal and remains the specific reversal agent for dabigatran, working as a monoclonal antibody fragment that binds free and thrombin-bound drug within minutes.

For warfarin, vitamin K (phytonadione) plus 4F-PCC remains standard for urgent reversal, and this sequence of preferred agents is now worth building into institutional bleeding protocols given the Andexxa gap.

Antiplatelet-associated bleeding has no specific pharmacologic antidote in routine use, so management centers on platelet transfusion for life-threatening hemorrhage in patients on potent P2Y12 inhibitors, mechanical hemostasis, and simply allowing the drug to wear off given the short half-lives of cangrelor and the GPIIb/IIIa agents.

Reversal Agent Quick Reference

Situation	Preferred Reversal	Notes	Company / Ticker
Dabigatran, life-threatening bleed	Idarucizumab (Praxbind)	Specific monoclonal antibody fragment; rapid onset	Boehringer Ingelheim (private)
Apixaban / rivaroxaban, life-threatening bleed	4F-PCC (Kcentra)	Now first-line since Andexxa withdrawal	OTC: CSLLY
Apixaban / rivaroxaban, historical option	Andexanet alfa (Andexxa)	Withdrawn from U.S. market Dec 22, 2025; do not order	NASDAQ: AZN
Warfarin, urgent reversal	Vitamin K + 4F-PCC	Vitamin K alone is too slow for active bleeding	Generic / CSLLY
Potent P2Y12 inhibitor, major bleed or urgent surgery	Platelet transfusion	No specific antidote exists; timing informed by drug half-life	Not applicable

Case Vignette 1: Reversal Decision

A 78-year-old on apixaban for atrial fibrillation presents with a large spontaneous intracranial hemorrhage six hours after her last dose.

Before the Andexxa withdrawal, many centers would have reached for andexanet alfa; the correct 2026 approach is immediate 4F-PCC dosed per institutional protocol, since andexanet is no longer commercially available and its risk-benefit profile no longer favored its use even before the recall.

Case Vignette 2: Antiplatelet Selection at PCI

A 61-year-old smoker presents with an NSTEMI and undergoes drug-eluting stent placement in the mid-LAD with a high thrombus burden noted on angiography.

A reasonable strategy pairs aspirin with ticagrelor for at least 12 months given its guideline-preferred status over clopidogrel in ACS, with intraprocedural cangrelor or a GPIIb/IIIa agent reserved for bailout if there is angiographic evidence of thrombus or slow flow.

Quick Reference by Indication

The single most useful organizing principle in antithrombotic therapy is matching the drug class to the clot's origin: cardiac/venous stasis clots respond to anticoagulants, while arterial/platelet-rich clots respond to antiplatelets, and several indications require both.

Indication	First-Line Class	Typical Agent(s)	Notes
Nonvalvular atrial fibrillation	Anticoagulant	Apixaban, rivaroxaban, dabigatran, edoxaban	Warfarin if mechanical valve or significant mitral stenosis
Venous thromboembolism (DVT/PE)	Anticoagulant	Apixaban or rivaroxaban (no lead-in needed)	Warfarin bridged with heparin in antiphospholipid syndrome
STEMI/NSTEMI, medically managed	Antiplatelet (dual)	Aspirin + ticagrelor or clopidogrel	Anticoagulant (heparin) added acutely, not chronically
Post-PCI with stent	Antiplatelet (dual)	Aspirin + ticagrelor, prasugrel, or clopidogrel	Duration individualized by bleeding vs ischemic risk
High thrombus burden PCI / bailout	Antiplatelet (IV)	Cangrelor or a GPIIb/IIIa inhibitor	Reserved for high-risk or complex lesions
Secondary stroke/TIA prevention (non-cardioembolic)	Antiplatelet	Aspirin, clopidogrel, or short-course dual therapy	Factor XIa inhibitors under regulatory review for this space
Stable CAD or symptomatic PAD	Antiplatelet ± anticoagulant	Aspirin or clopidogrel; low-dose rivaroxaban + aspirin in select patients	Dual-pathway inhibition per the COMPASS trial strategy
Mechanical heart valve	Anticoagulant	Warfarin	DOACs are contraindicated in this population
LVAD / mechanical circulatory support	Anticoagulant + antiplatelet	Warfarin plus aspirin	Device-specific protocols apply

What's Next: Factor XIa Inhibitors

The next anticoagulant class targets factor XI/XIa, a node in the intrinsic pathway that appears to contribute more to pathological clot amplification than to normal hemostasis.

Asundexian (Bayer) is furthest along regulatory-wise: it received FDA Priority Review in May 2026 for secondary stroke prevention after non-cardioembolic ischemic stroke or high-risk TIA, based on the OCEANIC-STROKE trial, though it does not yet have routine approval for any indication.

Abelacimab (Anthos Therapeutics, a privately held company with no public ticker) posted a striking safety signal in the Phase 2b AZALEA-TIMI 71 trial, cutting major or clinically relevant non-major bleeding by 62% compared with rivaroxaban in patients with atrial fibrillation.

Its Phase 3 efficacy readout, the LILAC-TIMI 76 stroke-prevention trial, is tracked publicly on ClinicalTrials.gov and represents the pivotal data investors and clinicians are both watching.

Milvexian (Bristol Myers Squibb and Johnson & Johnson) is being tested across multiple settings, including the post-acute coronary syndrome population in the LIBREXIA-ACS program, positioning it as a potential add-on to antiplatelet therapy rather than a stand-alone AF drug.

The shared thesis across this class, summarized well by recent pharmacy literature, is a safer alternative to DOACs with similar efficacy and materially reduced bleeding, though as of this writing none has full U.S. approval for a cardiovascular indication.

Factor XIa Inhibitor Pipeline Snapshot (July 2026)

Agent	Modality	Lead Indication	Regulatory Status	Company / Ticker
Asundexian	Oral small molecule	Secondary stroke prevention post-TIA/stroke	FDA Priority Review (accepted May 2026)	OTC: BAYRY
Abelacimab	Monoclonal antibody	AF stroke prevention	Phase 3 (LILAC-TIMI 76) ongoing	Anthos Therapeutics (private)
Milvexian	Oral small molecule	Post-ACS secondary prevention	Phase 3 (LIBREXIA program) ongoing	NYSE: BMY NYSE: JNJ

Practical Takeaways for Clinical Decision-Making

Choice among the four current DOACs still hinges on renal function, drug interactions, and cost, with apixaban generally preferred in patients with higher bleeding risk based on its trial-level safety profile.

Warfarin remains non-negotiable for mechanical valves and moderate-to-severe mitral stenosis, where no DOAC has demonstrated safety or efficacy.

Ticagrelor or prasugrel are generally preferred over clopidogrel after ACS in patients without a bleeding contraindication, though clopidogrel remains reasonable for elderly or high-bleeding-risk patients.

Every institution should update its massive-bleeding and reversal protocols now to remove Andexxa as an option and substitute 4F-PCC as first-line for factor Xa inhibitor–associated bleeding.

Factor XIa inhibitors are not yet prescribable for any cardiovascular indication in the U.S. as of July 2026, but asundexian's Priority Review timeline suggests a possible approval decision within this cycle, worth flagging for both clinical planning and portfolio watchlists.

Bottom Line

Anticoagulants own atrial fibrillation and venous thromboembolism, antiplatelets own acute coronary syndrome and PCI, warfarin persists for valve disease, the Andexxa withdrawal has quietly made 4F-PCC the default reversal strategy for factor Xa inhibitors, and factor XIa inhibitors led by asundexian and abelacimab are the space to watch for a potentially lower-bleeding anticoagulant future.

Watch Next

• Factor XI Inhibitors Explained — search results, YouTube
• DOAC Reversal Strategies After Andexxa Withdrawal — search results, YouTube
• Dual Antiplatelet Therapy Duration After PCI — search results, YouTube
• AZALEA-TIMI 71 Abelacimab Data Review — search results, YouTube

References

1. FDA Safety Communication: Update on the Safety of Andexxa, December 18, 2025.
2. Bayer: FDA Accepts NDA for Asundexian Under Priority Review, May 2026.
3. HCPLive: Abelacimab Limits Bleeding Events in AZALEA-TIMI 71.
4. Pharmacy Times: Factor XI Inhibitors — The Future of Anticoagulation.
5. ClinicalTrials.gov: AZALEA-TIMI 71 / LILAC-TIMI 76 Study Record.
6. TCTMD: New AF Guideline Emphasizes Early Rhythm Control.
7. GoodRx: Antiplatelet Drugs Class Overview, 2026.
8. GoodRx: Blood Thinner Medications Pricing Overview, 2026.

Physician education disclaimer: This article is intended for licensed healthcare professionals as a clinical education summary and does not replace institutional protocols, full prescribing information, or individualized patient assessment.

Financial disclaimer: Ticker symbols and pricing figures are provided for thematic and educational context only, reflect a specific point in time, and do not constitute investment advice or a recommendation to buy or sell any security; consult a licensed financial advisor before making investment decisions.

Cardiology & Capital Markets Briefing · For medical professional audiences

Structural Heart · Physician-Investor Briefing

Age and Early TAVR for Asymptomatic Severe Aortic Stenosis: What the Latest Data Mean for Practice and Portfolios

A closer look at how patient age reshapes the risk-benefit calculus of early intervention, and what it signals for the companies behind the valves.

Cardiology · Structural Heart Disease · 8 min read

Case Vignette

A 68-year-old asymptomatic executive with severe aortic stenosis and a peak aortic jet velocity of 4.6 m/s asks whether he should wait for symptoms or proceed now, since he feels completely well and has an upcoming board meeting he does not want to miss. His Society of Thoracic Surgeons risk score is low, his stress test is negative, and his echocardiogram shows preserved ejection fraction. This is precisely the scenario in which age-stratified trial data now offer a clearer answer than watchful waiting once did.

The Old Paradigm Is Cracking

For six decades, guidelines told clinicians to wait for symptoms before replacing a severely stenotic aortic valve.

That approach assumed intervention carried enough procedural risk to offset the danger of a diseased valve sitting quietly inside the heart.

Transcatheter aortic valve replacement has changed that math by making the procedure fast, minimally invasive, and remarkably low-risk in appropriately selected patients.

The randomized EARLY TAVR trial tested this shift directly by randomizing 901 asymptomatic patients with severe AS to either early intervention or guideline-recommended surveillance.

Primary Results at a Glance

Outcome	Early TAVR (n=455)	Clinical Surveillance (n=446)
Composite: death, stroke, or unplanned CV hospitalization	26.8%	45.3%
Death	8.4%	9.2%
Stroke	4.2%	6.7%
Unplanned CV hospitalization	20.9%	41.7%
Crossed over to AVR by 3.8 years	—	87.0%

The hazard ratio for the primary composite endpoint was 0.50, meaning early intervention roughly halved the risk compared with waiting for symptoms to appear.

Nearly nine in ten patients assigned to surveillance eventually needed valve replacement anyway, just later and after accumulating more risk along the way.

Figure 1. Key EARLY TAVR outcomes at a median follow-up of 3.8 years.

Why Age Changes the Answer

A late-breaking analysis presented at the Society for Cardiovascular Angiography and Interventions 2025 meeting asked whether a patient's age should influence the timing decision.

Older age was associated with higher rates of death, stroke, or heart failure hospitalization out to five years in both study arms, which is unsurprising on its own.

What stood out was that the relative benefit of early intervention was not confined to the elderly; it was substantial across the age spectrum, including the youngest enrolled patients.

Age-Stratified Benefit of Early TAVR

Age Group	Standout Finding at 5 Years
65–69 years	Stroke risk 0% with early TAVR vs 13% with surveillance; roughly six-fold lower rate of death, stroke, or hospitalization (4.7% vs 25.6%)
70–79 years	Consistent directional benefit with early TAVR across the composite endpoint
>80 years	Four-fold reduction in stroke with early TAVR compared with surveillance

The takeaway from the trial's lead investigators was that early TAVR should be favored over surveillance across essentially all age groups above the trial's 65-year inclusion threshold, since the composite endpoint consistently favored intervention.

This matters clinically because many physicians have intuitively reserved early intervention for older, frailer patients rather than younger ones who "still feel fine."

The data suggest the opposite framing may be more accurate: younger asymptomatic patients with severe AS may have the most to gain from acting early, particularly with respect to stroke prevention.

Figure 2. Simplified decision pathway informed by EARLY TAVR age-stratified findings.

The Market Side: Who Builds These Valves

The trial's balloon-expandable device is Edwards Lifesciences' SAPIEN platform, and the company remains the dominant player in transfemoral TAVRNYSE: EW.

Medtronic's self-expanding Evolut platform is the other major branded competitor in this spaceNYSE: MDT.

Expanding the addressable population from symptomatic to asymptomatic severe AS could meaningfully widen the eligible patient pool for both companies, since asymptomatic severe AS is common in aging populations and previously went untreated until symptoms emerged.

Structural Heart Device Makers at a Glance

Company	Ticker	Relevant Platform	Analyst Consensus	12-Month Price Target
Edwards Lifesciences	NYSE: EW	SAPIEN transcatheter valve family	Buy (27 analysts)	~$100.60 (+21% from current)
Medtronic	NYSE: MDT	Evolut self-expanding valve family	Buy (29 analysts)	~$97.84 (+16% from current)

Edwards reported second-quarter 2026 TAVR sales growth of roughly 10.5%, with overall company revenue guidance raised for the year, reflecting continued structural heart momentum even as the stock trades well below its 52-week high.

Both companies' near-term growth narratives depend partly on guideline committees eventually endorsing a broader "treat earlier" posture for asymptomatic severe AS, since current guidelines still center on symptom onset or biomarkers of decompensation as triggers for intervention.

What the Procedure Actually Costs

Cost Component	Approximate Figure
Device cost (SAPIEN 3 valve system)	~$30,000–$32,500
Median Medicare payment, full procedure	~$37,865
Median commercial insurance price	~$71,312 (varies ~2.6x by hospital and ~1.9x by insurer)
Median cash price	~$78,000

These figures come from a 2024 Circulation abstract analyzing the Turquoise Health pricing database, which found substantial regional and payer-level variation in what TAVR actually costs a given patient or system.

Extending early intervention to a much larger asymptomatic population raises legitimate health-system cost questions even though individual clinical outcomes favor earlier treatment.

Bottom Line

Age alone should no longer be the deciding factor in whether an asymptomatic patient with severe AS gets early TAVR, since benefit was consistent from the youngest enrolled patients through those over 80. The composite outcome data support a strategy shift toward earlier intervention in appropriately selected, low-surgical-risk patients rather than waiting for symptoms or crossover, which occurred in 87% of the surveillance group anyway. For the executive in the vignette above, a 68-year-old with a negative stress test and low surgical risk sits squarely inside the population that appears to benefit most, particularly regarding stroke prevention.

Physician Education Disclaimer: This article is intended for medical education purposes for physician readers and does not constitute individualized clinical guidance; treatment decisions should follow current professional society guidelines and shared decision-making with each patient.

Financial Disclaimer: Stock prices, analyst price targets, and financial data referenced above are approximate, time-sensitive, and change frequently; this content is for informational purposes only and does not constitute investment advice, and readers should consult a licensed financial advisor before making investment decisions.

Videos

NEJM: Early TAVR for Asymptomatic Severe Aortic Stenosis — trial overview

References

1. Transcatheter Aortic-Valve Replacement for Asymptomatic Severe Aortic Stenosis, New England Journal of Medicine.
2. EARLY TAVR and EVOLVED: Early Intervention in Patients With Asymptomatic AS?, American College of Cardiology.
3. EARLY TAVR Analysis Measures Influence of Patient Age on Outcomes, Cardiac Interventions Today / SCAI 2025.
4. Prices for Transcatheter Aortic Valve Repair Vary Significantly by US Insurance Company, Circulation.
5. A Review of the Cost Effectiveness of TAVR Versus SAVR, PMC.
6. Edwards Lifesciences (EW) Stock Overview, StockAnalysis.com.
7. Medtronic (MDT) Stock Overview, StockAnalysis.com.

This article synthesizes publicly available clinical trial data, professional society summaries, and financial market data current as of late July 2026 for a physician-investor audience.

Finerenone Elevated, GLP-1 Therapies Expanded in Updated ACC Consensus for HFpEF

 July 2026 Cardiology Update

Heart failure with preserved ejection fraction (HFpEF) now accounts for more than half of all heart failure cases, and treatment options continue to expand. In its updated 2026 Expert Consensus Decision Pathway for HFpEF (Kittleson et al., JACC 2026), the American College of Cardiology (ACC) emphasizes a modern treatment strategy built around SGLT2 inhibitors, finerenone, and incretin-based therapies — while highlighting the growing overlap between HFpEF and cardiovascular-kidney-metabolic (CKM) syndrome.


Diagnosis First

The ACC stresses that clinicians must first confirm that symptoms such as dyspnea, edema, and exercise intolerance truly result from HFpEF. Alternative diagnoses — including kidney disease, liver disease, valvular heart disease, hypertrophic cardiomyopathy, and cardiac amyloidosis — should be excluded before initiating treatment. The diagnosis of HFpEF remains more challenging than HFrEF because cardinal physical examination findings of elevated jugular venous pressure or pulmonary congestion may not be evident at rest.

The H2FPEF score (range 0–9) integrates clinical and echocardiographic variables — obesity, hypertension requiring ≥2 medications, atrial fibrillation, pulmonary hypertension, age >60, and elevated E/e' — to estimate HFpEF probability. A score >5 indicates more than 95% probability of HFpEF, while a score of 0–1 indicates less than 25% probability. Intermediate scores warrant exercise stress echocardiography or invasive hemodynamic testing.

Importantly, natriuretic peptide thresholds require adjustment for obesity: approximately 20% of HFpEF patients with obesity have normal natriuretic peptide levels. Recent evidence suggests a rule-out NT-proBNP threshold of <50 pg/mL (rather than <125 pg/mL) improves sensitivity, particularly in patients with BMI ≥35 kg/m².


SGLT2 Inhibitors Remain Foundational

The updated pathway provides its strongest endorsement yet for SGLT2 inhibitors, supported by the landmark EMPEROR-Preserved and DELIVER trials. In EMPEROR-Preserved, empagliflozin 10 mg daily reduced the composite of cardiovascular death or hospitalization for heart failure by 21% (HR 0.79; 95% CI 0.69–0.90; P<0.001) in 5,988 patients with LVEF >40%. In DELIVER, dapagliflozin 10 mg daily achieved an 18% reduction in the same composite endpoint (HR 0.82; 95% CI 0.73–0.92; P<0.001) in 6,263 patients. Benefits were consistent regardless of diabetes status, and dapagliflozin demonstrated statistically significant reductions within just two weeks of treatment initiation.

A meta-analysis of nine randomized controlled trials involving over 20,000 patients confirmed that SGLT2 inhibitors significantly reduce the risk of cardiovascular death or heart failure hospitalization (HR 0.83; 95% CI 0.76–0.90) and heart failure hospitalization alone (HR 0.75; 95% CI 0.68–0.84) in HFpEF. These agents should be initiated in all patients with HFpEF lacking contraindications and can be used with eGFR ≥20 mL/min/1.73 m².


Finerenone Moves Into the Spotlight

A major update is the inclusion of finerenone (Kerendia) as a preferred nonsteroidal mineralocorticoid receptor antagonist (MRA). In the FINEARTS-HF trial, 6,001 patients with heart failure and LVEF ≥40% were randomized to finerenone (maximum dose 20–40 mg daily) or placebo. Over a median follow-up of 32 months, finerenone reduced the composite of total worsening heart failure events and cardiovascular death by 16% (rate ratio 0.84; 95% CI 0.74–0.95; P=0.007), driven primarily by an 18% reduction in worsening heart failure events (rate ratio 0.82; 95% CI 0.71–0.94; P=0.006). This benefit was consistent across the full spectrum of ejection fractions, from LVEF <50% through ≥60%, and across all prespecified subgroups — including patients with and without diabetes, CKD, and concurrent SGLT2 inhibitor or GLP-1 receptor agonist use.

Finerenone now carries an FDA-approved indication to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visits in adults with heart failure and LVEF ≥40%. Compared with traditional steroidal MRAs — for which evidence in HFpEF remains limited to post-hoc analyses (Class 2b in current U.S. guidelines) — finerenone offers proven cardiovascular and renal benefits with a more favorable hyperkalemia profile, making it an increasingly important component of optimal HFpEF therapy.

A cross-trial analysis by Vaduganathan et al. (Nature Medicine, 2026) estimated that combined SGLT2 inhibitor + finerenone therapy reduces the risk of cardiovascular death or first worsening heart failure event by 31% (HR 0.69; 95% CI 0.59–0.81). In patients with LVEF <60%, the addition of sacubitril/valsartan (ARNI) to this combination yielded a 39% reduction (HR 0.61; 95% CI 0.48–0.77) — translating to an estimated 3.6 to 4.9 additional years free from cardiovascular death or heart failure events in a 65-year-old patient. These gains were meaningful across a broad age range, from 55 to 85 years.


GLP-1 and GIP/GLP-1 Agonists for Obesity-Related HFpEF

Recognizing the strong relationship between obesity and HFpEF, the ACC now emphasizes the use of incretin-based therapies. Both semaglutide and tirzepatide have demonstrated significant improvements in weight loss, exercise capacity, symptoms, and quality of life — and for patients with overweight or obesity, these therapies target a major driver of HFpEF pathophysiology rather than simply addressing congestion.

In the STEP-HFpEF program, 1,145 patients with HFpEF (LVEF ≥45%) and BMI ≥30 kg/m² were randomized to semaglutide 2.4 mg weekly or placebo. Semaglutide significantly improved quality of life (KCCQ scores), 6-minute walk distance, and body weight, with a pooled analysis showing a 73% reduction in time to first heart failure event (HR 0.27; 95% CI 0.12–0.56).

In the SUMMIT trial, 731 patients with HFpEF (LVEF ≥50%) and obesity were randomized to tirzepatide (target 15 mg subcutaneously weekly) or placebo over a median of 104 weeks. Tirzepatide reduced the composite of cardiovascular death or worsening heart failure by 38% (HR 0.62; 95% CI 0.41–0.95; P=0.026), with a 56% reduction in worsening heart failure resulting in hospitalization (HR 0.44; 95% CI 0.22–0.87). Health status improved by 6.9 points on the KCCQ-CSS (P<0.001), and 6-minute walk distance increased by 18.3 meters (P<0.001). Mechanistically, tirzepatide reduced systolic blood pressure by 5 mmHg, estimated blood volume by 0.58 liters, and C-reactive protein by 37%, while preserving estimated glomerular filtration rate — suggesting benefits extend beyond weight loss to include volume-pressure unloading and anti-inflammatory effects.

A large real-world cohort study of nearly 100,000 patients with cardiometabolic HFpEF (JAMA, 2025) confirmed these findings, demonstrating more than 40% risk reduction for the composite of heart failure hospitalization or all-cause mortality with both semaglutide (HR 0.58) and tirzepatide (HR 0.42) compared with sitagliptin. In head-to-head comparison, tirzepatide showed no meaningful advantage over semaglutide (HR 0.86; 95% CI 0.70–1.06).


HFpEF and CKM Syndrome: An Integrated Approach

One of the most important themes of the updated consensus is the recognition that HFpEF often exists within the broader framework of cardiovascular-kidney-metabolic (CKM) syndrome. The 2026 AHA/ACC/ADA/ASN CKM Guideline defines CKM syndrome as a progressive spectrum from excess adiposity (stage 1) through metabolic risk factors and CKD (stage 2), subclinical CVD (stage 3), to clinical CVD including heart failure (stage 4).

Many HFpEF patients simultaneously have:

- Obesity

- Type 2 diabetes

- Chronic kidney disease

- Hypertension

- Coronary artery disease

Importantly, therapies such as SGLT2 inhibitors, finerenone, semaglutide, and tirzepatide provide benefits that extend beyond heart failure, improving cardiovascular, renal, and metabolic health simultaneously. For patients with HFmrEF or HFpEF within the CKM framework, first-line treatment includes SGLT2 inhibitors and diuretics for congestion, with emerging data supporting finerenone as a key addition. Beta-blockers are not recommended for HFpEF in the absence of secondary indications (e.g., atrial fibrillation, symptomatic coronary artery disease).


Practical Clinical Takeaways

The ACC's updated roadmap for HFpEF recommends:

✅ Confirming the diagnosis and excluding mimics such as amyloidosis, HCM, and valvular disease

✅ Initiating SGLT2 inhibitors (empagliflozin or dapagliflozin) in all eligible patients

✅ Adding finerenone when appropriate, particularly in patients with concomitant CKD or diabetes

✅ Considering GLP-1 receptor agonists (semaglutide) or GIP/GLP-1 agonists (tirzepatide) in patients with obesity (BMI ≥30 kg/m²)

✅ Aggressively treating comorbidities including atrial fibrillation, hypertension, diabetes, chronic kidney disease, and sleep apnea

✅ Managing HFpEF through the broader lens of CKM syndrome


Bottom Line

HFpEF is no longer a therapeutic desert. Evidence from EMPEROR-Preserved, DELIVER, FINEARTS-HF, STEP-HFpEF, and SUMMIT has transformed management. The combination of SGLT2 inhibitors, finerenone, and incretin-based therapies offers clinicians an expanding arsenal of treatments that improve outcomes while addressing the interconnected cardiovascular, kidney, and metabolic abnormalities that characterize modern HFpEF. A cross-trial analysis projects that early combination therapy with SGLT2 inhibitors and finerenone — with the addition of ARNI in selected patients — could afford patients nearly 4 to 5 additional years free from cardiovascular death or heart failure events.


Key References

- 2026 ACC Expert Consensus Decision Pathway for HFpEF (Kittleson et al., JACC 2026)

- EMPEROR-Preserved (Anker et al., NEJM 2021)

- DELIVER (Solomon et al., NEJM 2022)

- FINEARTS-HF (Solomon et al., NEJM 2024)

- STEP-HFpEF (Kosiborod et al., NEJM 2023)

- SUMMIT (Packer et al., NEJM 2025)

- Lifetime Benefits of Comprehensive Medical Therapy (Vaduganathan et al., Nature Medicine 2026)

- 2026 AHA/ACC/ADA/ASN CKM Guideline (Ndumele et al., Circulation 2026)

Physician & Investor Briefing · Imaging & Physiology

The Burnout Behind the Console: Cardiovascular Imaging's Workforce Crisis

New survey data puts a number on a problem imagers have felt for years, and the fix looks structural, not spiritual.

Cardiology Practice & Markets Reading time: ~6 minutes

Nearly three in five cardiovascular imaging physicians now describe themselves as burned out, according to new survey data presented at the 2026 Society of Cardiovascular Computed Tomography meeting.

That figure lands in a field that has been treated as a niche corner of cardiology and radiology, even as its clinical footprint has exploded.

The survey's authors argue that burnout here is not the generic, well-documented phenomenon seen across medicine, but a distinct symptom of a supply-demand mismatch that is about to get worse.

For a physician-investor audience, that distinction matters, because the same forces driving physicians out of the reading room are also reshaping which companies profit from the imaging pipeline.

A Niche Field, a Loud Signal

The survey drew responses from 248 physicians, two-thirds of whom identified as cardiologists and one-third as radiologists, with 66% in mid-career between ages 36 and 55.

Fifty-eight percent reported feelings of burnout, and more than two-thirds said they routinely work outside scheduled hours, a pattern researchers called "pajama time."

Thirty-seven percent reported working after hours every single day.

Physicians reporting burnout were more than twice as likely to say they were considering leaving practice compared with their non-burned-out peers (21% versus 9%).

Clinical workload and workflow inefficiency outweigh administrative burden as the leading drivers, a pattern distinct from prior burnout literature in general cardiology.

Not the Usual Suspects

Notably, the survey found no statistically significant difference in burnout rates by sex or age group, which diverges from patterns reported in broader physician burnout literature.

Respondents reporting burnout were also significantly less likely to say they had adequate institutional support.

The society's outgoing president framed this as evidence that burnout in cardiac imaging is not a personal deficiency but a structural feature of how imaging work is currently organized.

The Supply-Demand Undertow

The immediate trigger for burnout is workload, but the underlying pressure is a worsening imbalance between imaging demand and available imager capacity.

Workforce modeling cited by the American College of Radiology points to a shortfall of nearly 20,000 radiology and related specialists by 2036.

On the cardiology side, separate projections reported by the American College of Cardiology estimate that the ratio of cardiovascular patients to cardiologists will rise from roughly 1,087-to-1 in 2025 to 1,700-to-1 by 2035.

That same analysis found that counties with a cardiologist density of about 13 per 100,000 residents had the lowest cardiovascular mortality, yet only a small fraction of U.S. counties currently meet that threshold.

A near-56% increase in patient load per cardiologist over a decade is the macro backdrop against which imaging burnout is unfolding.

Why a Meditation App Won't Fix It

A recurring theme at the meeting was skepticism toward wellness interventions aimed at individual coping rather than workflow redesign.

Physicians in the audience pointed to duplicated work, such as both a cardiologist and a radiologist independently reading the same cardiac CT angiogram, without billing structures that reflect either party's effort.

Junior physicians, whose productivity is often measured in RVUs, are described as disproportionately affected by this kind of uncompensated duplicate work.

The consistent ask from frontline imagers was fewer logins, fewer redundant systems, and workflow tools that reduce clicks rather than add wellness programming on top of an unchanged workload.

Where Technology and Capital Intersect

The gap between imaging demand and imager supply is precisely the opening that health-system administrators and investors are pointing toward workflow automation and AI-assisted reporting to fill.

GE HealthCare Technologies NASDAQ: GEHC, the imaging-equipment spinout from General Electric, has been expanding digital and AI-enabled imaging platforms aimed at consolidating fragmented reading workflows.

RadNet NASDAQ: RDNT, an outpatient diagnostic imaging operator, has built out a dedicated artificial-intelligence segment intended to help radiologists handle rising volume without proportional headcount growth.

Both companies illustrate the same physician-investor tension at the heart of this story: tools marketed as burnout relief are also, from a balance-sheet perspective, productivity and margin levers.

Whether a given workflow tool actually reduces a physician's daily click count, versus simply enabling a health system to expect more volume from the same imager, is an empirical question practices should ask before adopting any platform.

Table 1. Publicly Traded Companies With Exposure to Cardiovascular Imaging Workflow and Workforce Capacity

Company	Ticker	Relevant Exposure	Analyst Consensus	Approx. Price Target
GE HealthCare Technologies	GEHC	CT/MR imaging hardware, AI-enabled digital workflow (Allia, MIM Anyware)	Buy	~$79–82
RadNet	RDNT	Outpatient imaging centers; dedicated AI/Digital Health segment	Strong Buy	~$80–90

Prices and analyst targets are approximate and sourced from StockAnalysis.com as of late July 2026; markets move daily and these figures should be independently verified before any investment decision.

Table 2. Burnout Drivers vs. Systems-Level Interventions Discussed at SCCT 2026

Reported Driver	% Citing Driver	Systems-Level Response Discussed
Clinical workload	60%	Panel/protocol standardization; shared reading pools
Inefficient workflows	52%	Single sign-on, consolidated reading platforms
Administrative burden	42%	Ancillary staff support; reduced duplicate documentation
Leadership/institutional culture	42%	Physician-inclusive governance; RVU/billing reform
Work-life integration	41%	Protected non-clinical time; realistic panel sizing
After-hours work ("pajama time")	35%	Workload caps; after-hours coverage pools

Case Vignette

A 42-year-old interventional cardiologist with a growing structural heart imaging practice notices she is finishing CT and echo reports most nights after her children are asleep.

Her hospital recently added a wellness stipend covering a meditation app subscription, but her reading queue and documentation burden have not changed.

Recognizing "pajama time" as a workflow signal rather than a personal failing, she brings volume and turnaround-time data to her division chief and proposes a shared overnight reading pool with the radiology department.

This case illustrates how the SCCT 2026 survey data can be used at the practice level: as a concrete argument for structural change rather than another individual wellness intervention.

Bottom Line

Burnout among cardiovascular imagers is running at 58%, driven primarily by workload and workflow inefficiency rather than administrative tasks alone, and it tracks a widening gap between imaging demand and specialist supply projected to persist through the mid-2030s.

For clinicians, the actionable lever is reframing burnout as a workforce and systems problem worth raising with leadership, not a personal resilience deficit to be managed with wellness apps.

For physician-investors, the same workforce gap is the demand driver behind imaging-equipment and AI-workflow companies, though it is worth distinguishing tools that genuinely reduce physician workload from those that primarily enable higher throughput expectations.

Physician education disclaimer: This article summarizes published survey data and professional society commentary for educational purposes and does not constitute clinical, employment, or wellness guidance for any individual physician or practice.

Financial disclaimer: This article is for general informational purposes only and does not constitute investment advice or a recommendation to buy or sell any security; stock prices, ratings, and price targets are time-sensitive and subject to change without notice. Consult a licensed financial advisor before making investment decisions.

Watch

• Physician Burnout: It's Not a Resiliency Deficit — panel discussion on systems-level causes of physician burnout.
• American College of Cardiology — Official Video Channel — ongoing coverage of cardiovascular workforce and well-being topics.

References

1. Burnout Uniquely Rampant Among Cardiac Imagers. TCTMD, July 20, 2026.
2. Burnout Fueling Workforce Woes. ACR Bulletin, American College of Radiology.
3. A Workforce in Crisis: Navigating the Cardiovascular Clinician Shortage. Cardiology Magazine, American College of Cardiology.
4. GE HealthCare Technologies (GEHC) Stock Overview. StockAnalysis.com.
5. RadNet (RDNT) Stock Overview. StockAnalysis.com.

Prepared for physician-investor education. Not medical or financial advice.

Imaging & Physiology · Cath Lab Safety · Physician-Investor Briefing

One Scan, Three Answers: How CT Is Redrawing Coronary Risk Assessment — and Why the Cath Lab Itself Needs Protecting

Anatomy, physiology, and inflammatory biology are converging inside a single non-invasive scan, while a new multisociety consensus argues the people performing these procedures deserve the same modernization.

July 23, 2026 · 9-minute read · For cardiology, radiology, and physician-investor audiences

Coronary computed tomography angiography has quietly graduated from a gatekeeper test to a full risk-stratification platform.

A joint ACC/AHA chest pain guideline already assigns CCTA its strongest possible recommendation for evaluating both acute and stable symptoms in patients without known disease.

The Society of Cardiovascular Computed Tomography has called that shift decades in the making, since roughly 15 to 20 million U.S. patients fall into the intermediate-to-high-risk category the guideline targets.

New data presented this month push the technology further still, showing that a single CT acquisition can now flag vascular inflammation on top of calcium and plaque, even when no contrast is given.

Meanwhile, a separate multisociety document is asking a parallel question: if imaging technology has evolved this quickly, why hasn't operator radiation protection kept pace?

This briefing walks through both threads and the practice, and portfolio, implications for each.

Figure 1. A single CCTA or non-contrast gated CT acquisition can now inform anatomic, physiologic, and inflammatory risk assessment.

Why CCTA Earned Its "Game-Changer" Label

The 2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR chest pain guideline gave CCTA a Class 1, Level A recommendation, the strongest rating a diagnostic test can receive.

That rating reflected more than a decade of trial evidence showing CCTA works as a non-invasive, cost-effective front-line test.

The test's real advantage is that it no longer answers a single question.

A single acquisition can characterize anatomy through calcium scoring and plaque volume, physiology through CT-derived fractional flow reserve, and now biology through quantitative inflammation markers.

CAD-RADS 2.0 formalizes part of this shift by adding plaque burden modifiers, so a patient with only mild stenosis but heavy plaque burden can still be flagged for aggressive lipid-lowering therapy.

That distinction matters clinically because a normal CCTA carries a very high negative predictive value, yet a meaningful share of future infarctions arise from non-obstructive plaque that a stress test alone would miss.

Quantifying Inflammation: The Next Layer on Top of Calcium

New data presented at the 2026 Society of Cardiovascular Computed Tomography meeting extend this idea directly into the inflammation space.

Investigators used the ORFAN study cohort, drawing on 19,159 patients from nine United Kingdom centers followed for a median of 6.8 years.

The tool in question, a CT-derived fat attenuation index (FAI) score, measures inflammatory changes in the fat surrounding the coronary arteries.

Across the full cohort, the FAI score significantly improved risk stratification beyond calcium scoring and plaque volume alone.

The most striking finding was that this benefit was strongest in patients with a zero calcium score, a group traditionally reassured and discharged from further workup.

In that zero-calcium subgroup, each standard-deviation increase in FAI score corresponded to roughly a 50% higher hazard of cardiovascular mortality.

Critically, the prognostic signal held up whether the scan used contrast or was a plain, non-contrast gated CT, which broadens the pool of patients who could benefit since most calcium-score-only scans are acquired without contrast.

A companion poster from the ongoing FORTIFY trial reinforced the point in a different population: post-MI patients already on optimized guideline-directed therapy.

Despite excellent medical management, roughly six in ten of these well-treated patients still showed elevated coronary inflammation on CT.

That trial is testing an investigational monoclonal antibody targeting oxidized LDL in patients with this kind of persistent inflammation, so a positive readout could eventually give clinicians a therapy to pair with the diagnostic signal.

The technology behind the FAI score is currently supported through research funding and a pilot program, and remains under regulatory review in the United States, so routine clinical availability and reimbursement are not yet established.

One clinician involved in the research also noted a future use case worth watching: serial FAI scanning to track whether anti-inflammatory or lipid-lowering therapy is actually working, something a rising calcium score cannot tell you since calcification itself increases with statin therapy.

Figure 2. Coronary inflammation added the greatest incremental prognostic value in patients otherwise classified as low-risk by calcium score, based on ORFAN cohort data.

Case Vignette

A 54-year-old with a strong family history of premature coronary disease and an LDL cholesterol in the 190s undergoes a coronary calcium scan that returns a score of zero.

Under a purely calcium-based framework, this result might be reassuring enough to defer statin intensification.

If the same non-contrast dataset were run through an inflammation-quantification algorithm and returned an elevated fat attenuation index, the clinical conversation would shift meaningfully toward earlier, more aggressive lipid-lowering therapy despite the "clean" calcium result.

This scenario illustrates exactly the population the newest ORFAN analysis identifies as gaining the most from inflammation quantification: patients a calcium score alone would under-classify.

Cath Lab Radiation Safety: A Parallel Modernization Push

While imaging is getting smarter, a separate multisociety effort is asking whether protecting the people who perform these procedures has kept pace.

A new consensus statement led by the Society for Cardiovascular Angiography and Interventions, alongside echocardiography, rhythm, interventional radiology, and vascular surgery societies, argues that traditional lead-apron-based ALARA practice is now outdated.

Enhanced radiation protection devices (ERPDs), including mobile and ceiling-mounted barrier systems, radiation-attenuating drapes, and robotic or remote-controlled systems, have been shown to cut operator and staff radiation exposure by as much as 99% compared with standard lead-apron protection.

The document is notable for its tone: rather than reminding operators to wear thicker lead, it calls on hospitals, manufacturers, and regulators to share responsibility for adopting these systems.

Authors specifically point to fluoroscopy equipment manufacturers as bearing primary responsibility for building radiation-minimizing features directly into their systems.

They also emphasize that real-time dosimetry should accompany every ERPD, since it gives operators immediate feedback during the learning curve of adopting lower-lead or lead-free workflows.

State-level variability complicates adoption, since some states allow reduced or no lead apparel with certain systems while others do not yet formally recognize these newer barrier technologies.

The consensus authors call for a national certification program for fluoroscopy lab personnel, a standardized dose-monitoring platform, and a national occupational exposure registry to bring consistency to this landscape.

The stakes are not abstract: musculoskeletal injury from wearing heavy lead for decades, alongside radiation-related health risks, has long been described as an accepted occupational hazard of interventional practice.

Representative ERPD Categories Discussed in the Consensus Statement

Protection Category	Primary Beneficiary	Reported Exposure Reduction
Ceiling/table-mounted transparent barrier systems	Operator	≥90%
Panel-based transparent barrier systems	Operator plus assistant	≥90%
Body-worn robotic/suspended shielding	Operator	Up to 99%
Configurable radiation-protection systems	Entire staff	≥90%

Figures reflect ranges reported in the SCAI/ASE/HRS/SIR/SVS expert consensus statement; individual system performance varies by procedure type and room configuration.

The Investor Lens: Imaging Hardware, AI Analytics, and Cath Lab Safety

None of the diagnostic companies behind FAI quantification or coronary AI plaque analysis are publicly traded, so thematic exposure for now runs mainly through the CT hardware and broader device makers that build and sell the scanners and cath lab equipment these tools run on.

Company / Technology	Role	Ticker	Analyst Consensus
GE HealthCare (CT imaging systems)	Cardiac CT hardware, AI-enabled acquisition	NASDAQ: GEHC	Buy
Siemens Healthineers (CT imaging systems)	Cardiac CT hardware, Imaging segment	OTC: SMMNY	Strong Buy
Boston Scientific (interventional cardiology)	Cath lab devices; broader interventional exposure	NYSE: BSX	Strong Buy
Caristo Diagnostics (CaRi-Heart / FAI technology)	FAI score analytics	no ticker	—
Abcentra (orticumab, FORTIFY trial)	Investigational anti-inflammatory antibody	no ticker	—
Egg Medical, Rampart IC, StemRad, Biotronik, Image Diagnostics (ERPD systems)	Enhanced radiation protection devices	private / segment of larger co.	—

Where a company is private, exposure is best framed thematically through the publicly traded imaging and device peers rather than through the company itself.

Regulatory clearance timelines matter here: FAI-based inflammation scoring remains under U.S. review, so the addressable market and reimbursement pathway are not yet defined domestically.

Analyst sentiment on the large-cap imaging names has been volatile this year, with several 2026 price-target revisions on both GEHC and BSX, so position sizing should account for that volatility rather than treat these as pure plays on any single technology theme.

Bottom Line

A single CT acquisition can now deliver anatomic, physiologic, and inflammatory risk data, and the inflammatory layer appears most valuable precisely in patients a calcium score would otherwise reassure.

Separately, a multisociety consensus is pushing cath lab radiation protection from an individual responsibility toward a regulatory and institutional one.

Both threads point toward the same broader trend: modernizing tools that have functionally not changed in decades, whether that tool is a risk calculator or a lead apron.

Financial exposure to date runs through CT hardware and device incumbents rather than the still-private diagnostic-analytics innovators themselves.

Physician education disclaimer: This article is intended for physician education and does not constitute individualized clinical guidance; treatment decisions should be based on current guidelines and individual patient assessment.

Financial disclaimer: This content is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell any security; stock prices, analyst ratings, and price targets are time-sensitive and subject to change. Consult a licensed financial advisor before making investment decisions.

---

Watch

• TCTMD YouTube channel — conference coverage and topical discussions on coronary imaging and cath lab practice

References

1. 2021 AHA/ACC Chest Pain Guideline Perspectives. American College of Cardiology.
2. CCTA Receives Multiple Class 1, Level A Recommendations in 2021 New Chest Pain Guideline. Society of Cardiovascular Computed Tomography.
3. Quantifying Inflammation Can Add to CV Risk Prediction Even in No-Contrast Scans. TCTMD, July 2026.
4. FORTIFY Trial Record. ClinicalTrials.gov.
5. SCAI Calls for 'Regulation-Mandated' Enhanced Radiation Safety. TCTMD, July 2026.